In particular, recent studies have demonstrated that pembrolizumab (an anti-PD-1 monoclonal antibody) had improved efficacy and long-term clinical benefit for the subgroup of patients with microsatellite instability-high (MSI-H)/DNA mismatch repair-deficient (dMMR) CRC [7, 8]. This evidence concerns the gene PDCD1 and colorectal carcinoma.